RedHill Biopharma: Up as COVID-19 drug passes fourth independent safety review

Redhill Biopharma

09/04/2021 13:31

** U.S.-listed shares of Israeli drug developer  RDHL.O 
rise 5.2% to $7.06 premarket
    ** Co says global midstage study of oral drug opaganib in
patients hospitalized with severe COVID-19 pneumonia received
unanimous recommendation from independent panel to continue
 urn:newsml:reuters.com:*:nPn4JYxJQa
    ** Says recommendation follows a fourth independent Data
Safety Monitoring Board (DSMB) safety review 
    ** Adds total opaganib safety database now expanded to about
380 patients after most recent review
    ** Opaganib works by potentially minimizing likelihood of
viral resistance - co
    ** Up to last close, RDHL stock down ~17% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))